AMERICAN REGENT, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1967-01-01
- Employees
- 501
- Market Cap
- -
Iron Sucrose in Non-Dialysis Dependent (NDD-CKD) Pediatric Patients
- First Posted Date
- 2008-07-23
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- American Regent, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT00721188
- Locations
- 🇺🇸
Luitpold Pharmaceuticals, Norristown, Pennsylvania, United States
Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- American Regent, Inc.
- Target Recruit Count
- 708
- Registration Number
- NCT00703937
- Locations
- 🇺🇸
Luitpold Pharmaceuticals, Norristown, Pennsylvania, United States
Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- American Regent, Inc.
- Target Recruit Count
- 735
- Registration Number
- NCT00704353
- Locations
- 🇺🇸
Luitpold Pharmaceuticals, Norristown, Pennsylvania, United States
Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- American Regent, Inc.
- Target Recruit Count
- 161
- Registration Number
- NCT00704028
- Locations
- 🇺🇸
Luitpold Pharmaceuticals, Norristown, Pennsylvania, United States
Intravenous Iron Metabolism in Restless Legs Syndrome
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2017-05-11
- Lead Sponsor
- American Regent, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT00685815
- Locations
- 🇺🇸
The Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-10-24
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- American Regent, Inc.
- Target Recruit Count
- 513
- Registration Number
- NCT00548691
- Locations
- 🇺🇸
Luitpold Pharmaceuticals, Norristown, Pennsylvania, United States
Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-10-24
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- American Regent, Inc.
- Target Recruit Count
- 2018
- Registration Number
- NCT00548860
- Locations
- 🇺🇸
Luitpold Pharmaceuticals, Norristown, Pennsylvania, United States
Taxoprexin® Treatment for Advanced Primary Cancers of the Liver
- First Posted Date
- 2007-01-17
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- American Regent, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT00422877
- Locations
- 🇺🇸
University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- American Regent, Inc.
- Target Recruit Count
- 456
- Registration Number
- NCT00395993
- Locations
- 🇺🇸
Luitpold Pharmaceuticals, Inc., Norristown, Pennsylvania, United States
Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in Subjects Who Display Postpartum Anemia
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- American Regent, Inc.
- Target Recruit Count
- 361
- Registration Number
- NCT00396292
- Locations
- 🇺🇸
Luitpold Pharmaceuticals, Norristown, Pennsylvania, United States
© Copyright 2024. All Rights Reserved by MedPath